When asked how she spends her free time, Rebecca Driscoll says she thinks about cancer pretty much twenty-four hours per day, seven days per week. While she may also love to cook, design floral arrangements for events, and create jewelry, Rebecca’s fierce dedication to helping people with cancer is immediately evident to anyone who encounters her. Rebecca joined Cancer Commons as CEO in July… Read more »
Cancer Commons’ most recent webinar, A New Technology for Rapid Therapy Guidance, was held virtually December 14, 2022. This presentation and Q&A session introduced viewers to a new cancer therapy guidance test that is designed to predict which cancer drugs are most likely to be effective for individual cancer patients. Cancer Commons CEO Rebecca Driscoll introduced Clifford Reid, PhD (Founder and CEO) and Dennis Watson (VP… Read more »
We invite everyone to join us to learn about a cancer therapy guidance test designed to predict which cancer drugs are most likely to be effective for individual cancer patients. Cancer Commons is partnering with Travera with the shared goal of helping late-stage cancer patients who are running out of therapeutic options and time. A New Technology for Rapid Therapy Guidance will be held December 14,… Read more »
Cancer Commons’ most recent webinar, Tools and Strategies to Take Your Cancer Management to the Next Level, was held virtually on November 9, 2022. This dynamic one-hour session introduced participants to three passionate advocates making a difference in the lives of cancer patients and caregivers: Cancer Commons CEO Rebecca Driscoll, Courage Groups founder Mike Looney, PhD, and We’re in This Together (WiTT) CEO Rahul Mahadevan. The webinar was… Read more »
We are proud to share that this month, Commons Scientist Kaumudi Bhawe, PhD, presented a poster at the 2022 TargetCancer Foundation Think Tank on Advancing Gastroesophageal Cancer Research. The Think Tank is a unique, two-day scientific meeting addressing the challenges facing researchers and clinicians in gastroesophageal cancer. This highly interactive and discussion-based meeting is designed to promote information-sharing and idea generation in an effort… Read more »
Cancer Commons, in partnership with the Musella Foundation For Brain Tumor Research & Information, has a pilot study underway that seeks to improve outcomes for current glioblastoma (GBM) patients and identify promising therapies for development. The study will use genomic sequencing and other biomarker testing to help identify individualized treatment regimens and will capture and analyze clinical outcomes to inform treatment for future patients.… Read more »
We invite everyone to join the fourth webinar in Cancer Commons’ Pat Looney Educational Series for Client Empowerment, which will wrap up the series for the year with a presentation of vitally important information and tools for patients and caregivers. Tools and Strategies to Take Your Cancer Management to the Next Level, will be offered virtually and free of charge on Wednesday, November 9, at… Read more »
Cancer Commons is dedicated to helping more cancer patients understand their cancer diagnoses and find the most effective testing, treatments, and clinical trials. A new collaboration with Michelle’s Place Cancer Resource Center in Temecula, California, will allow us to connect with local patients, and serve as a model for future partnerships with community-based advocacy groups. Michelle’s Place offers a myriad of programs designed to… Read more »
Cancer Commons’ most recent webinar, Testing Matters—Understanding Cancer Biomarker Testing and How It Applies to You, was held virtually on September 14, 2022. During the webinar, Cancer Commons Scientists Kaumudi Bhawe, PhD, and Adrienne Nugent, PhD, provided plain-language explanations of different types of biomarker testing and described why, how, when, and where to access testing. They also answered audience questions. The webinar was the… Read more »
Cancer Commons is excited to share our latest collaboration with the Pancreatic Cancer Action Network (PanCAN). The purpose of the grant-funded project is for Cancer Commons to help pancreatic cancer patients referred by PanCAN achieve their best possible treatment outcomes and enroll in a longitudinal study assessing individualized therapies and contributing to improved outcomes for future pancreatic cancer patients. Patients will be entered in… Read more »